ReviewDrug resistance updates : reviews and commentaries in antimicrobial and anticancer chemotherapy
Contribution of tumoral and host solute carriers to clinical drug response.
Review in Drug resistance updates : reviews and commentaries in antimicrobial and anticancer chemotherapy. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 33 citations in OpenAlex.
- Targeting Lipid Transport Pathways: A New Frontier in Colorectal Cancer Therapy.Digestive diseases and sciences · 2025Review
- Expression status of p53 and organic cation transporter 1 is correlated with poor response to preoperative chemotherapy in esophageal squamous cell carcinoma.World journal of surgical oncology · 2022Article
- Solute carrier family 12 member 8 (SLC12A8) is a potential biomarker and related to tumor immune cell infiltration in bladder cancer.Bioengineered · 2021Article
- SLC46A1 Haplotype with Predicted Functional Impact has Prognostic Value in Breast Carcinoma.Molecular diagnosis & therapy · 2021Article
- The Expression Profiles of ADME Genes in Human Cancers and Their Associations with Clinical Outcomes.Cancers · 2020Article
- Article
- Modeling cancer drug response through drug-specific informative genes.Scientific reports · 2019Article
- Harnessing Solute Carrier Transporters for Precision Oncology.Molecules (Basel, Switzerland) · 2017Review
- Inhibitory effects of chemotherapeutics on human organic anion transporter hOAT4.International journal of biochemistry and molecular biology · 2016Article
- Cyclin-dependent kinase inhibitor dinaciclib potently synergizes with cisplatin in preclinical models of ovarian cancer.Oncotarget · 2015Article
- Dynamic modulation of thymidylate synthase gene expression and fluorouracil sensitivity in human colorectal cancer cells.PloS one · 2015Article
- Organic cation transporter 2 for predicting cisplatin-based neoadjuvant chemotherapy response in gastric cancer.American journal of cancer research · 2015Article
- Impact of Expression Levels of Platinum-uptake Transporters Copper Transporter 1 and Organic Cation Transporter 2 on Resistance to Anthracycline/Taxane-based Chemotherapy in Triple-negative Breast Cancer.Breast cancer : basic and clinical research · 2015Article
- How drugs get into cells: tested and testable predictions to help discriminate between transporter-mediated uptake and lipoidal bilayer diffusion.Frontiers in pharmacology · 2014Review
- Modulation of OATP1B-type transporter function alters cellular uptake and disposition of platinum chemotherapeutics.Molecular cancer therapeutics · 2013Article
- Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 2 institutions in 2 countries.
Funding
Abstract
Members of the solute carrier family of transporters are responsible for the cellular uptake of a broad range of endogenous compounds and xenobiotics in multiple tissues. Several of these solute carriers are known to be expressed in cancer cells or cancer cell lines, and decreased cellular uptake of drugs potentially contributes to the development of resistance. As result, the expression levels of these proteins in humans have important consequences for an individual's susceptibility to certain drug-induced side effects, interactions, and treatment efficacy. In this review article, we provide an update of this rapidly emerging field, with specific emphasis on the direct contribution of solute carriers to anticancer drug uptake in tumors, the role of these carriers in regulation of anticancer drug disposition, and recent advances in attempts to evaluate these proteins as therapeutic targets.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.